On September 21, 2012, the Senate joined the House in approving H.R. 6433, the FDA User Fee Corrections Act of 2012. The bill would allow the FDA to collect all generic drug user fees authorized by the recently-enacted FDA Safety and Innovation Act for FY 2013, rather than a reduced level of fees allowed under the short-term funding bill also cleared by Congress on September 21. H.R. 6433 is now awaiting the President’s signature.